Perivascular Inflammation in Pulmonary Arterial Hypertension
Cells, 2020 Perivascular inflammation is a prominent pathologic feature in most animal models of pulmonary hypertension (PH) as well as in pulmonary arterial hypertension (PAH) patients.
Yijie Hu +3 more
semanticscholar +1 more source
Current and future treatments of pulmonary arterial hypertension
British Journal of Pharmacology, 2020 Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin, and NO pathways has significantly improved outcomes. However, for the vast
N. Sommer +8 more
semanticscholar +1 more source
Impact of the updated hemodynamic definitions on diagnosis rates of pulmonary hypertension
Pulmonary Circulation, 2020 We evaluated whether updated pulmonary hypertension definitive criteria proposed in sixth World Symposium on Pulmonary Hypertension had an impact on diagnosis of overall pulmonary hypertension and pre-capillary and combined pre- and post-capillary ...
Seda Tanyeri +15 more
doaj +1 more source
Sildenafil for the Treatment of Pulmonary Hypertension in Pediatric Patients [PDF]
, 2009 Sildenafil is a phosphodiesterase 5 inhibitor widely used for the treatment of pulmonary hypertension in children. Despite limited available safety and efficacy evidence, use of sildenafil continues to increase.
Ebenroth, Eric S. +3 more
core +2 more sources
MicroRNA-483 amelioration of experimental pulmonary hypertension. [PDF]
, 2020 Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit.
Bai, Liang +22 more
core +1 more source
Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4.
PLoS ONE, 2020 BACKGROUND:The knowledge of hereditary predisposition has changed our understanding of Pulmonary Arterial Hypertension. Genetic testing has been widely extended and the application of Pulmonary Arterial Hypertension specific gene panels has allowed its ...
Ignacio Hernandez-Gonzalez +15 more
doaj +1 more source
Pulmonary Circulation, 2021 Inhalation profiles to support use of dry powder inhalers for drug delivery in patients with pulmonary arterial hypertension have not been reported. We aimed to evaluate the inspiratory flow pattern associated with low and medium flow resistance dry ...
Mariana Faria-Urbina +4 more
doaj +1 more source
Animal Models of Pulmonary Arterial Hypertension and Their Application in Drug Research
Shiyan dongwu yu bijiao yixue, 2023 Pulmonary arterial hypertension is a clinical syndrome characterized by pulmonary vascular remodeling causing increased vascular resistance, which will lead to right heart failure and even death if left untreated.
YU Jiahui, GONG Qian, ZHUANG Lenan
doaj +1 more source
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
New England Journal of Medicine, 2013 BACKGROUND Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using
T. Pulido +18 more
semanticscholar +1 more source
Oxidative stress-dependent activation of collagen synthesis is induced in human pulmonary smooth muscle cells by sera from patients with scleroderma-associated pulmonary hypertension [PDF]
, 2014 Pulmonary arterial hypertension is a major complication of systemic sclerosis. Although oxidative stress, intima hyperplasia and a progressive vessel occlusion appear to be clearly involved, the fine molecular mechanisms underpinning the onset and ...
Boin, Francesco +8 more
core +2 more sources